Role of Intravenous Immunoglobulin in Dermatologic Disorders

Amber, Kyle T.; Shiu, Jessica; Ferris, Katherine; Grando, Sergei A.

doi:10.1007/978-3-319-66884-0_39

Cited by 3 publications

(8 citation statements)

References 336 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, FcRn inhibition has the potential to decrease MHC antigen presentation to T cells and survival of autoantibodies in the circulation, the two fundamental forces in disease pathogenesis. Additionally, IVIg efficacy is thought to work through saturation of the FcRn receptors, further supporting the role of FcRn in pemphigus pathogenesis . However, IVIg has several other immunoregulatory mechanisms which may enhance the effect of FcRn inhibition in mitigating disease.…”

Section: Evolving Therapeutic Targetsmentioning

confidence: 97%

“…Additionally, IVIg efficacy is thought to work through saturation of the FcRn receptors, further supporting the role of FcRn in pemphigus pathogenesis. 41,155 However, IVIg has several other immunoregulatory mechanisms which may enhance the effect of FcRn inhibition in mitigating disease. SYNT001a is an IgG4 humanized monoclonal antibody which specifically inhibits FcRn function.…”

Section: Inhibitory Antibodiesmentioning

confidence: 99%

“…Numerous advances in our understanding of these diseases have allowed for treatment strategies that go beyond non‐specific immunosuppression . The application of rituximab and intravenous immunoglobulin (IVIg) in combination has shown how different aspects of these diseases can be effectively targeted . While these therapies have become more accepted as a standard of care, corticosteroids are still generally required for prolonged periods of time for acute disease .…”

Section: Introductionmentioning

confidence: 99%

“…34,35 The application of rituximab and intravenous immunoglobulin (IVIg) in combination has shown how different aspects of these diseases can be effectively targeted. [36][37][38][39][40][41] While these therapies have become more accepted as a standard of care, corticosteroids are still generally required for prolonged periods of time for acute disease. [42][43][44][45][46][47][48] Likewise, relapses are common, especially in shorter treatment protocols, rather than protracted protocols.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

Kridin

Kowalski

Kneiber

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Autoimmune blistering diseases comprise a group of heterogenous conditions characterized by the loss of tolerance and subsequent development of autoantibodies targeting epidermal and subepidermal adhesion proteins. Blisters and erosions form on the skin and mucous membranes leading to significant morbidity and mortality. Traditional therapies rely on systemic immunosuppression. Advancements in our understanding of the pathophysiology of pemphigus and pemphigoid have led to the development of molecules which target specific pathways involved in induction and perpetuation of disease. In this review, we outline the novel therapeutic strategies including B‐cell depletion, T‐regulatory cell repletion, cell signalling inhibitors and small molecular inhibitors, inhibitory monoclonal antibodies, as well as complement inhibition. We additionally review their current level of clinical evidence. We lastly review therapeutics targets gleaned from the experimental epidermolysis bullosa acquisita mouse model. These emerging treatments offer an exciting progression from basic science discoveries that have the potential to transform the treatment paradigm in autoimmune blistering diseases.

show abstract

Section: Evolving Therapeutic Targetsmentioning

confidence: 97%

Section: Inhibitory Antibodiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

Kridin

Kowalski

Kneiber

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Although introduction of rituximab (RTX) provided for a favorable outcome, the high relapse rate, that is, up to 80%, precludes successful use of RTX as a monotherapy. Intravenous immunoglobulin (IVIg) is being increasingly utilized as off‐label therapy for a variety of autoimmune and inflammatory diseases, including PV and pemphigus foliaceus (PF) (reviewed in). In contrast to RTX and conventional immunosuppressive agents (ISA), IVIg does not cause immunosuppression that endangers patients with infectious complications.…”

Section: Introductionmentioning

confidence: 99%

Retrospective analysis of a single‐center clinical experience toward development of curative treatment of 123 pemphigus patients with a long‐term follow‐up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion‐protecting drugs

Grando

2018

Int J Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy

Kianfar

Dasdar

Daneshpazhooh

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

Autoimmune bullous diseases (AIBDs) are a group of rare blistering dermatoses of the mucous membrane and/or skin. The efficacy, safety and treatment durability of intravenous immunoglobulin (IVIg) as an alternative treatment should be explored to systematically review the available literature regarding treatment outcomes with IVIg in AIBD patients. The predefined search strategy was incorporated into the following database, MEDLINE/PubMed, Embase, Scopus and Web of Science on 18 July 2022.Sixty studies were enrolled using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The use of IVIg alone or combined with rituximab was reported in 500 patients with pemphigus, 82 patients with bullous pemphigoid, 146 patients with mucous membranes pemphigoid and 19 patients with epidermolysis bullosa acquisita. Disease remission with IVIg therapy and RTX + IVIg combination therapy were recorded as 82.8% and 86.7% in pemphigus, 88.0% and 100% in bullous pemphigoid and 91.3% and 75.0% in mucous membrane pemphigoid, respectively. In epidermolysis bullosa acquisita, treatment with IVIg led to 78.6% disease remission; no data were available regarding the treatment with RTX + IVIg in this group of patients. Among all the included patients, 37.5% experienced at least one IVIg-related side effect; the most common ones were headaches, fever/chills and nausea/vomiting. The use of IVIg with or without rituximab had a favourable clinical response in patients with AIBDs. IVIg has no major influence on the normal immune system, which makes its utilization for patients with AIBDs reasonable.

show abstract

Role of Intravenous Immunoglobulin in Dermatologic Disorders

Cited by 3 publications

References 336 publications

From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy

Contact Info

Product

Resources

About